Find drug development pipeline and deal Updates information

Lead Product(s): RXC007

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

Details:

Preclinical data with compounds from Redx’s ROCK2 programme have demonstrated robust anti-fibrotic effects in a range of industry-standard in vivo models.

Lead Product(s): OSP-101

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Altavant Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition January 08, 2020

Details:

This acquisition expands Altavant’s pipeline to include OSP-101, a novel inhaled interleukin-1 receptor antagonist (IL-1Ra) with orphan drug designation from the U.S. Food and Drug Administration.

Lead Product(s): AT-100

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $15.5 million Upfront Cash: Undisclosed

Deal Type: Series C Financing January 08, 2020

Details:

This funding will enable clinical development of AT-100 (rhSP-D), while also supporting preclinical research in influenza, respiratory syncytial virus (RSV) and cystic fibrosis.